Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study

INTRODUCTION: To compare the efficacy of innovator ranibizumab (iRBZ—Accentrix, Novartis, India) vs. biosimilar ranibizumab (bRBZ, Razumab-Intas, India) in eyes with diabetic macular edema (DME) in an Indian population. METHODS: Data of patients with DME who underwent at least three injections of iR...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Debdulal, Sengupta, Sabyasachi, Mondal, Soumen, Boral, Subhendu, Das, Arnab, Sinha, Tushar Kanti, Bhattacharya, Ranabir, Maitra, Ritobroto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927574/
https://www.ncbi.nlm.nih.gov/pubmed/35075621
http://dx.doi.org/10.1007/s40123-022-00463-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927574/
https://www.ncbi.nlm.nih.gov/pubmed/35075621
http://dx.doi.org/10.1007/s40123-022-00463-5

Ejemplares similares